Drug-induced Myelotoxicity in Patients with Crohn’s Disease
), Fransiscus Nikodemus Hosea(2),
(1) Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
(2) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
Corresponding Author
Abstract
As a chronic granulomatous disease, Crohn’s disease (CD) poses a significant insinuation on morbidity and low quality of life. Long-term treatment is needed to control the disease activity. Observation and evaluation of disease activity are principal practices in treating CD, and sometimes clinicians tend to overlook the adverse effects of therapy that may occur and resemble disease progression.Hereby, we presented a 76-year-old female with a 10-year history of Crohn’s disease who came to our emergency room with general weakness one week before admission. She complained of hematochezia and abdominal pain in the last month. She had been taking mesalazine 2x500 mg PO and azathioprine 2x50 mg PO in the previous three years. She was diagnosed with lung cancer six months before admission and had been prescribed erlotinib 1x150 mg PO in the last six weeks. Upon admission, pancytopenia was found in the blood study. Hematochezia, along with anemia and abdominal pain, might occur due to either disease activity or the adverse effects of the medication.Thorough observation and clinical evaluation regarding disease activity and side effects are required to manage Crohn’s disease comprehensively.
Keywords
References
Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.
Roda G, Ng SC, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn’s disease. Nat Rev Dis Primers. 2020;6(1):1–20.
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22.
Wójcik B, Loga K, Włodarczyk M, Sobolewska-Włodarczyk A, Padysz M, Wiśniewska-Jarosińska M. Extraintestinal manifestations of Crohn’s disease. Prz Gastroenterol. 2016;11(3):218. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047972/
Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of Crohn’s disease. World J Gastroenterol. 2014;20(1):133–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886002/
Liu J, Zhou H, Zhang Y, Fang W, Yang Y, Hong S, et al. A Mendelian randomization study of the effects of Crohn’s disease on lung cancer. Ann Oncol. 2019;30(Suppl 2):ii18. Available from: https://www.annalsofoncology.org/article/S0923-7534(19)30204-2/fulltext
Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14(2):111–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863044/
Olfatifar M, Zali MR, Pourhoseingholi MA, Balaii H, Ghavami SB, Ivanchuk M, et al. The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: a modeling study. BMC Gastroenterol. 2021;21(1):1–8. Available from: https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-021-01745-1
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–7. Available from: https://pubmed.ncbi.nlm.nih.gov/26323879/
Rasmussen SN, Lauritsen K, Tage-Jensen U, Nielsen OH, Bytzer P, Jacobsen O, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22(7):877–83. Available from: https://pubmed.ncbi.nlm.nih.gov/3313678/
Mahida YR, Jewell DP. Slow-release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion. 1990;45(2):88–92. Available from: https://pubmed.ncbi.nlm.nih.gov/2190851/
Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastroenterol. 1994;19(4):278–82. Available from: https://pubmed.ncbi.nlm.nih.gov/7876505/
Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2(5):379–88. Available from: https://pubmed.ncbi.nlm.nih.gov/15118975/
Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology. 1993;104(5):1293–301. Available from: https://pubmed.ncbi.nlm.nih.gov/8482443/
Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113(5):1465–73. Available from: https://pubmed.ncbi.nlm.nih.gov/9352848/
Zhou XS, Lu YY, Gao YF, Shao W, Yao J. Bone marrow inhibition induced by azathioprine in a patient without mutation in the thiopurine S-methyltransferase pathogenic site: a case report. World J Clin Cases. 2021;9(17):4230–7. Available from: https://pubmed.ncbi.nlm.nih.gov/34141785/
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34(8):1081–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374358/
UpToDate. Overview of azathioprine and mercaptopurine use in inflammatory bowel disease. Available from: https://www.uptodate.com/contents/overview-of-azathioprine-and-mercaptopurine-use-in-inflammatory-bowel-disease
Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, et al. Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis. Inflamm Bowel Dis. 2017;23(3):461–72. Available from: https://academic.oup.com/ibdjournal/article/23/3/461/4561095
StatPearls [Internet]. Tyrosine kinase inhibitors. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563322/
Gass-Jégu F, Gschwend A, Gairard-Dory AC, et al. Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review. Lung Cancer. 2016;99:76–8. doi:10.1016/j.lungcan.2016.06.012
Zippi M, De Quarto A, Marzano C, Cassieri C, Crispino P, Traversa G, et al. Severe gastrointestinal bleeding due to erlotinib and celecoxib therapy: additional effect? Ital J Med. 2016;11(1):75–7. doi:10.4081/itjm.2016.689
Stathopoulos GP, Trafalis D, Athanasiou A, Bardi G, Chandrinou H. Serious hematologic complications following erlotinib treatment. Anticancer Res. 2010;30:973–6.
Article Metrics
Abstract View
: 438 times
Download : 275 times
DOI: 10.24871/2522024%p
Refbacks
- There are currently no refbacks.
